Javascript must be enabled to continue!
Development and Validation of an AI-Based Decision Support Tool (PROMETHEUS) for Predicting Methotrexate Success in Ectopic Pregnancy
View through CrossRef
Abstract
Objective
E
ctopic pregnancy (EP), a life-threatening condition in early pregnancy, requires accurate and timely management to reduce morbidity and mortality. While methotrexate therapy is a widely used non-invasive treatment, predicting its success remains challenging. This study introduces PROMETHEUS (Prediction of Methotrexate for Ectopic Pregnancy Treatment Success), an AI-driven decision support tool designed to assist clinicians in selecting optimal treatment strategies, aiming to minimize unnecessary surgeries and enhance patient outcomes.
Methods
A retrospective nested cohort study analyzed 602 cases of EP diagnosed at Tepecik Education and Research Hospital between 2013 and 2023. Patients were grouped based on treatment received: single-dose methotrexate, two-dose methotrexate, surgery, or surgery following failed methotrexate therapy. Twenty-four clinical parameters were recorded, with 22 included in the final analysis. PROMETHEUS was developed using 15 AI algorithms, including Bagging, J48, and Random Forest. The dataset was divided into training (80%) and validation (20%) cohorts.
Results
Key findings highlighted significant clinical differences between treatment groups, such as larger ectopic mass sizes and altered blood counts in patients requiring surgery after methotrexate failure. All algorithms used for modelling Prometheus achieved high accuracy (p < 0.001), of them Bagging algorithm demonstrated an optimal balance between sensitivity (92.7%) and specificity (94.8%), along with the highest AUC (93.8%) (p < 0.001).
Conclusion
PROMETHEUS represents an innovation in ectopic pregnancy management, offering a high-accuracy AI-based decision support tool to optimize methotrexate therapy selection. This innovation has the potential to reduce treatment-related morbidity, streamline clinical workflows, and enhance personalized care. Future multi-institutional studies are needed to validate PROMETHEUS or similar AI-based applications and expand their clinical applicability.
Synopsis; An AI-driven tool, PROMETHEUS, achieved 93.86% accuracy in predicting methotrexate success for ectopic pregnancy, optimizing treatment decisions and reducing unnecessary surgeries.
Springer Science and Business Media LLC
Title: Development and Validation of an AI-Based Decision Support Tool (PROMETHEUS) for Predicting Methotrexate Success in Ectopic Pregnancy
Description:
Abstract
Objective
E
ctopic pregnancy (EP), a life-threatening condition in early pregnancy, requires accurate and timely management to reduce morbidity and mortality.
While methotrexate therapy is a widely used non-invasive treatment, predicting its success remains challenging.
This study introduces PROMETHEUS (Prediction of Methotrexate for Ectopic Pregnancy Treatment Success), an AI-driven decision support tool designed to assist clinicians in selecting optimal treatment strategies, aiming to minimize unnecessary surgeries and enhance patient outcomes.
Methods
A retrospective nested cohort study analyzed 602 cases of EP diagnosed at Tepecik Education and Research Hospital between 2013 and 2023.
Patients were grouped based on treatment received: single-dose methotrexate, two-dose methotrexate, surgery, or surgery following failed methotrexate therapy.
Twenty-four clinical parameters were recorded, with 22 included in the final analysis.
PROMETHEUS was developed using 15 AI algorithms, including Bagging, J48, and Random Forest.
The dataset was divided into training (80%) and validation (20%) cohorts.
Results
Key findings highlighted significant clinical differences between treatment groups, such as larger ectopic mass sizes and altered blood counts in patients requiring surgery after methotrexate failure.
All algorithms used for modelling Prometheus achieved high accuracy (p < 0.
001), of them Bagging algorithm demonstrated an optimal balance between sensitivity (92.
7%) and specificity (94.
8%), along with the highest AUC (93.
8%) (p < 0.
001).
Conclusion
PROMETHEUS represents an innovation in ectopic pregnancy management, offering a high-accuracy AI-based decision support tool to optimize methotrexate therapy selection.
This innovation has the potential to reduce treatment-related morbidity, streamline clinical workflows, and enhance personalized care.
Future multi-institutional studies are needed to validate PROMETHEUS or similar AI-based applications and expand their clinical applicability.
Synopsis; An AI-driven tool, PROMETHEUS, achieved 93.
86% accuracy in predicting methotrexate success for ectopic pregnancy, optimizing treatment decisions and reducing unnecessary surgeries.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Playing Pregnancy: The Ludification and Gamification of Expectant Motherhood in Smartphone Apps
Playing Pregnancy: The Ludification and Gamification of Expectant Motherhood in Smartphone Apps
IntroductionLike other forms of embodiment, pregnancy has increasingly become subject to representation and interpretation via digital technologies. Pregnancy and the unborn entity...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Development and Validation of an AI-Based Decision Support Tool (PROMETHEUS) for Predicting Methotrexate Success in Ectopic Pregnancy
Development and Validation of an AI-Based Decision Support Tool (PROMETHEUS) for Predicting Methotrexate Success in Ectopic Pregnancy
Objective: E
ctopic pregnancy (EP), a life-threatening condition
in early pregnancy, requires accurate and timely management to reduce
morbidity and mortality. Wh...
P066: Methotrexate in the management of suspected ectopic pregnancy
P066: Methotrexate in the management of suspected ectopic pregnancy
Introduction: Early detection of ectopic pregnancy and careful management is critical to prevent adverse clinical outcomes, including fallopian tube rupture and future decreased fe...
Rare Presentation Heterogeneous Pregnancies
Rare Presentation Heterogeneous Pregnancies
It is done and corrected two cases in General Hospital, Babylon, Iraq Vaginal bleeding, scanty discharge that differs from the timing and amount of a normal menstrual cycle and / o...

